SQI Diagnostics (TSXV:SQD.H) - Stock Price, News & Analysis

SQD.H Stock Overview

A precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide.

About the company

SQD.H fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Does not have a meaningful market cap (CA$6M)

Negative shareholders equity

Shares are highly illiquid

Latest financial reports are more than a year old

+ 2 more risks

SQI Diagnostics Inc. Competitors

Titan Medical

TSX:TMD

CA$5.7m

Frequency Exchange

TSXV:FREQ

CA$6.4m

Scryb

CNSX:SCYB

CA$4.4m

ASEP Medical Holdings

CNSX:ASEP

CA$8.4m

Price History & Performance

Summary of all time highs, changes and price drops for SQI Diagnostics
Historical stock prices
Current Share Price	CA$0.015
52 Week High	CA$0.02
52 Week Low	CA$0.015
Beta	-0.38
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-90.91%
5 Year Change	-88.00%
Change since IPO	-99.23%

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Shareholder Returns

	SQD.H	CA Medical Equipment	CA Market
7D	0%	1.5%	0.3%
1Y	n/a	-7.1%	12.7%

Return vs Industry: Insufficient data to determine how SQD.H performed against the Canadian Medical Equipment industry.

Return vs Market: Insufficient data to determine how SQD.H performed against the Canadian Market.

Price Volatility

Is SQD.H's price volatile compared to industry and market?
SQD.H volatility
SQD.H Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	11.1%
Market Average Movement	8.0%
10% most volatile stocks in CA Market	16.7%
10% least volatile stocks in CA Market	3.0%

Stable Share Price: SQD.H has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine SQD.H's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Andrew Morris	www.sqidiagnostics.com

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow.

SQI Diagnostics Inc. Fundamentals Summary

How do SQI Diagnostics's earnings and revenue compare to its market cap?
SQD.H fundamental statistics
Market cap	CA$6.11m
Earnings (TTM)	-CA$19.14m
Revenue (TTM)	CA$3.05m

2.0x

P/S Ratio

-0.3x

P/E Ratio

Is SQD.H overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SQD.H income statement (TTM)
Revenue	CA$3.05m
Cost of Revenue	CA$3.19m
Gross Profit	-CA$140.00k
Other Expenses	CA$19.00m
Earnings	-CA$19.14m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.047
Gross Margin	-4.60%
Net Profit Margin	-628.51%
Debt/Equity Ratio	-103.3%

How did SQD.H perform over the long term?

See historical performance and comparison

SQD.H Stock Overview

Rewards

Risk Analysis

SQI Diagnostics Inc. Competitors

TSX:TMD

CA$5.7m

TSXV:FREQ

CA$6.4m

CNSX:SCYB

CA$4.4m

CNSX:ASEP

CA$8.4m

Price History & Performance

Recent News & Updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Shareholder Returns

Price Volatility

About the Company

SQI Diagnostics Inc. Fundamentals Summary

2.0x

-0.3x

Earnings & Revenue